Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194231 | 0.94 | KIT (0.49) | KITGAAPAK1PIK3CAMTOR | |
| SCHEMBL4196326 | 0.93 | GAA (0.57) | KITGAAPAK1PIK3CAMTOR | |
| SCHEMBL4192384 | 0.87 | GAA (0.53) | KITGAAPAK1PIK3CAMTOR | |
| SCHEMBL4190180 | 0.87 | KIT (0.52) | KITGAAPAK1PIK3CAMTOR | |
| SCHEMBL4198558 | 0.84 | ADRB2 (0.56) | KITPAK1ADRB2ADRB1ADRB3 | |
| SCHEMBL4196118 | 0.83 | PAK1 (0.55) | KITPAK1PIK3CAMTORADRB2 | |
| SCHEMBL4188880 | 0.81 | KIT (0.48) | KITPAK1PIK3CAMTORADRB2 | |
| SCHEMBL4187312 | 0.81 | KIT (0.48) | KITPAK1PIK3CAMTORADRB2 | |
| SCHEMBL4188891 | 0.80 | KIT (0.48) | KITGAAPIK3CAMTORADRB2 | |
| SCHEMBL4187370 | 0.80 | AKT1 (0.49) | KITPAK1PIK3CAMTORADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| EP-1899355-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893215-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135639-A1 | THIΞNOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135630-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | KIT 92/4885GAA 2155/4885PAK1 155/4885 |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | KIT 92/4885GAA 2155/4885PAK1 155/4885 |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | KIT 92/4885GAA 2155/4885PAK1 155/4885 |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, TPX2 | KIT 151/4885GAA 1784/4885PAK1 71/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | KIT 557/4885GAA 368/4885PAK1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.